Ardelyx (ARDX) said its drug Xphozah lowered serum phosphate levels and improved patient satisfaction in adults with chronic kidney disease on dialysis.
Patients taking Xphozah had an average one milligram per deciliter drop in serum phosphate, with almost half achieving reductions of at least that amount, the company said Friday in a statement.
In a separate survey, 63% of patients reported improved phosphate levels, and 69% said their outlook on phosphate control had improved, the company said.
The findings were based on data presented at the American Society of Nephrology's Kidney Week in Houston.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments